The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $21.50

Today's change-0.22 -1.01%
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $21.50

Today's change-0.22 -1.01%
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Osiris Therapeutics Inc down (U.S.)$0.22

Osiris Therapeutics Inc closed lower Tuesday, dropping (U.S.)$0.22 or 1.01% to (U.S.)$21.50. Shares have lost 1.87% over the last five days, but have gained 34.46% over the last year to date. This security has outperformed the S&P 500 by 42.50% during the last year.

Key company metrics

  • Open(U.S.) $21.91
  • Previous close(U.S.) $21.72
  • High(U.S.) $21.91
  • Low(U.S.) $21.23
  • Bid / Ask-- / --
  • YTD % change+34.46%
  • Volume125,107
  • Average volume (10-day)198,115
  • Average volume (1-month)175,303
  • Average volume (3-month)167,268
  • 52-week range(U.S.) $11.87 to (U.S.) $23.67
  • Beta0.93
  • Trailing P/E430.09×
  • P/E 1 year forward53.63×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.05
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.54%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue21191713
Total other revenue--------
Total revenue21191713
Gross profit16151310
Total cost of revenue5443
Total operating expense19181613
Selling / general / administrative1310119
Research & development2411
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income2110
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax211-1
Income after tax111-1
Income tax, total1000
Net income111-2
Total adjustments to net income--------
Net income before extra. items111-1
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items111-1
Inc. avail. to common incl. extra. items111-2
Diluted net income111-2
Dilution adjustment00----
Diluted weighted average shares35343534
Diluted EPS excluding extraordinary itemsvalue per share0.040.030.02-0.04
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.040.030.02-0.04